{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:39:46Z","timestamp":1777927186246,"version":"3.51.4"},"reference-count":5,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T00:00:00Z","timestamp":1495065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:p>The British Association for Sexual Health and HIV (BASHH) revised United Kingdom national guideline for the management of gonorrhoea in adults, 2011, identified five auditable outcome measures, namely, that all patients should receive first-line treatment, be screened or treated for chlamydial infection, have a test of cure (TOC), be offered written information and have partner notification carried out. The UK National Guideline for Gonorrhoea Testing, Clinical Effectiveness Group, BASHH, 2012, recommended in addition that all reactive nucleic acid amplification tests (NAATs) from pharynx and rectum should be confirmed by supplementary testing, using a second NAAT which detects a different nucleic acid target, all those with a positive NAAT for gonorrhoea should have culture and antimicrobial susceptibility testing and that TOC should be done by two weeks. Staff, associate specialist and specialty doctors performed a national audit against these standards. Data from 3233 cases were submitted; 8% of cases of gonorrhoea diagnosed in England, Scotland and Wales over this period. We found that 83% patients received first-line treatment with a reason for not doing so provided for 11%. TOC was documented for 62% and written information was offered to 41%. Results about supplementary testing were inconsistent. The results for the other outcomes were satisfactory.<\/jats:p>","DOI":"10.1177\/0956462417710602","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T08:20:31Z","timestamp":1495095631000},"page":"1450-1452","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Staff, associate specialist and specialty doctors\u2019 national audit on the management of gonorrhoea in the United Kingdom, 2015"],"prefix":"10.1177","volume":"28","author":[{"given":"Helen","family":"Mullan","sequence":"first","affiliation":[{"name":"Watford Sexual Health Centre, Central London Community Healthcare, Watford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Richards","sequence":"additional","affiliation":[{"name":"Newcastle Hospitals Foundation Trust, Community Health, New Croft Centre, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lee","sequence":"additional","affiliation":[{"name":"Spectrum Centre for Sexual Health, Trinity Walk, Wakefield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,5,18]]},"reference":[{"key":"bibr1-0956462417710602","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2011.011267"},{"key":"bibr2-0956462417710602","unstructured":"BASHH Clinical Effectiveness Group. United Kingdom National Guideline for Gonorrhoea Testing 2012. http:\/\/www.bashh.org\/guidelines (accessed 20 February 2016)."},{"key":"bibr3-0956462417710602","unstructured":"BASHH Clinical Effectiveness Group. BASHH statement on partner notification for sexually transmissible infections, https:\/\/www.bashh.org\/documents\/4445.pdf (2012, accessed 20 Nov 2016)."},{"key":"bibr4-0956462417710602","unstructured":"Public Health England. Surveillance of antimicrobial resistance to\n                      Neisseria gonorrhoeae\n                      , https:\/\/www.gov.uk\/government\/publications\/gonococcal-resistance-to-antimicrobials-surveillance-programme-grasp-report (2016, accessed 18 March 2017)."},{"key":"bibr5-0956462417710602","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2015-052220"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462417710602","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462417710602","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462417710602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:37:13Z","timestamp":1777675033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462417710602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,18]]},"references-count":5,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1177\/0956462417710602"],"URL":"https:\/\/doi.org\/10.1177\/0956462417710602","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,18]]}}}